Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Jackman

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Cancer|June 11, 2008
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesotheliomaDavid M Jackman, Hedy L Kindler, Beow Y Yeap, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
The introduction of systematic genomic testing for patients with non-small-cell lung cancerStephanie Cardarella, Taylor M Ortiz, Victoria A Joshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2012
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutationsStephanie Heon, Beow Y Yeap, Neal I Lindeman, et al.
Academic Radiology|November 2, 2010
CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical toolMizuki Nishino, Mengye Guo, David M Jackman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2014
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNAGeoffrey R Oxnard, Cloud P Paweletz, Yanan Kuang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsDavid M Jackman, Vincent A Miller, Leigh-Anne Cioffredi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2015
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung AdenocarcinomaAntonio Calles, Lynette M Sholl, Scott J Rodig, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancerRavi B Parikh, Angel M Cronin, David E Kozono, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2015
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung CancerAntonio Calles, Xiaoyun Liao, Lynette M Sholl, et al.
Oncotarget|March 19, 2015
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancerDavid M Jackman, Leigh A Cioffredi, Lorraine Jacobs, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Cancer|June 11, 2008
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesotheliomaDavid M Jackman, Hedy L Kindler, Beow Y Yeap, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
The introduction of systematic genomic testing for patients with non-small-cell lung cancerStephanie Cardarella, Taylor M Ortiz, Victoria A Joshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2012
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutationsStephanie Heon, Beow Y Yeap, Neal I Lindeman, et al.
Academic Radiology|November 2, 2010
CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical toolMizuki Nishino, Mengye Guo, David M Jackman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2014
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNAGeoffrey R Oxnard, Cloud P Paweletz, Yanan Kuang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsDavid M Jackman, Vincent A Miller, Leigh-Anne Cioffredi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2015
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung AdenocarcinomaAntonio Calles, Lynette M Sholl, Scott J Rodig, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancerRavi B Parikh, Angel M Cronin, David E Kozono, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2015
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung CancerAntonio Calles, Xiaoyun Liao, Lynette M Sholl, et al.
Oncotarget|March 19, 2015
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancerDavid M Jackman, Leigh A Cioffredi, Lorraine Jacobs, et al.
Pageof 6